Aurinia Pharmaceuticals (AUPH) Enters Long-Term Manufacturing Agreement with Lonza for Voclosporin
streetinsider. | December 20, 2016
After the close, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced it has entered into a long-term agreement with Lonza for the manufacture of voclosporin active pharmaceutical ingredient (API). This agreement follows a successful multi-year clinical manufacturing relationship where the companies have been refining the process and analytical methods to produce clinical and commercial supplies of voclosporin.